rubitecan

Suppliers

Names

[ Name ]:
rubitecan

[Synonym ]:
rubitecan
MFCD06656294
1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (4S)-
PYRIDOXINE 3,4-DIPALMITATE
9-nitro-20(s)-camptothecin
1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONE,4-ETHYL-4-HYDROXY-10-NITRO-, (4S)-
(4S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Orathecin

Chemical & Physical Properties

[ Density]:
1.6±0.1 g/cm3

[ Boiling Point ]:
816.3±65.0 °C at 760 mmHg

[ Melting Point ]:
182-186ºC

[ Molecular Formula ]:
C₂₀H₁₅N₃O₆

[ Molecular Weight ]:
393.350

[ Flash Point ]:
447.5±34.3 °C

[ Exact Mass ]:
393.096100

[ PSA ]:
127.24000

[ LogP ]:
1.38

[ Vapour Pressure ]:
0.0±3.1 mmHg at 25°C

[ Index of Refraction ]:
1.762

[ Storage condition ]:
Room temp

MSDS

Click to get detail MSDS

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
UQ0493300

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

(S)-4-ethyl-4-hydroxy-10-nitro-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-nitrobenzenesulfonate
(S)-4-ethyl-4-hydroxy-10-nitro-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl benzenesulfonate
(S)-4-ethyl-4-hydroxy-10-nitro-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-fluorobenzenesulfonate
Campathecin
(S)-10-Hydroxycamptothecin
9-Nitro-10-hydroxy camptothecin

DownStream

Articles

Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.

Int. J. Pharm. 340(1-2) , 29-33, (2007)

Pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin (9-NC) were compared after intravenous (i.v.) and intramuscular (i.m.) injection at a dose of 1.5mg/kg 9-NC solution. The co...

Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin.

Drug Dev. Ind. Pharm. 32(6) , 719-26, (2006)

9-Nitrocamptothecin (9-NC), a newly developed camptothecin derivative, had poor solubility in any pharmaceutically acceptable solvents. One way of improving the solubility is to formulate the drug int...

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

Mol. Cancer Ther. 5(8) , 2130-7, (2006)

Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I...